Voluntary nationwide recall: Brexafemme
Oct. 2023Pharmacy Updates
Scynexis, Inc. is recalling two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets. This drug is used as an antifungal for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC). Read the full text of the voluntary Brexafemme recall.
Recent Announcements
Clinical workflow changes through Epic®
Changes are coming for network providers that utilize Provider OnLine to submit specific information to UPMC Health Plan. Select activities that were previously completed in Provider OnLine will now transition to UPMC Health Plan Tapestry Link.Oct. 2026Important Notices
Provider Directory Updates and Required Attestation
As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).Oct. 2026Important Notices
CME Webinar: Navigating Grief Conversations
Please join us for a live, CME-accredited webinar on Thursday, Nov. 12, 2026, that will enhance your confidence and effectiveness in supporting patients dealing with loss & grief.Oct. 2026Education/Webinars